AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales ... coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling ...

Investors in AbbVie Inc. ABBV need to pay close attention ... It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is ...

Pharmaceutical giant AbbVie has inked another collaboration deal ... has also signed similar agreements with other Big Pharma companies, such as Novo Nordisk and Biogen. The company focuses ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

For the third year in a row, the hundreds of millions of dollars poured into commercials for AbbVie’s immunology blockbusters have earned the Big Pharma ... immunology giant, Sanofi and ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

Mehmet Oz, Trump's nominee to lead the Centers for Medicare and Medicaid Services, pledged to divest his investments in ...